181 related articles for article (PubMed ID: 32113902)
1. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients' Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers.
Kafatos G; Dube S; Burdon P; Demonty G; Flinois A; Leclerc M; Lowe K; Feudjo-Tepie M; Segaert S
Clin Colorectal Cancer; 2020 Jun; 19(2):100-108.e9. PubMed ID: 32113902
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
[TBL] [Abstract][Full Text] [Related]
3. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
[TBL] [Abstract][Full Text] [Related]
4. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
[TBL] [Abstract][Full Text] [Related]
5. Skin Toxicities During Colorectal Cancer Chemotherapy: Incidence and Pearls of Treatment in Our Experience.
Panariello L; Donnarumma M; Iaffaioli RV; Chiodini P; Annunziata MC; Peduto T; Fabbrocini G
Clin Colorectal Cancer; 2020 Dec; 19(4):e235-e242. PubMed ID: 32665093
[TBL] [Abstract][Full Text] [Related]
6. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors.
Peng Y; Li Q; Zhang J; Shen W; Zhang X; Sun C; Cui H
Biosci Trends; 2019 Jan; 12(6):537-552. PubMed ID: 30555112
[TBL] [Abstract][Full Text] [Related]
7. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer.
Bouché O; Ben Abdelghani M; Labourey JL; Triby S; Bensadoun RJ; Jouary T; Des Guetz G
World J Gastroenterol; 2019 Aug; 25(29):4007-4018. PubMed ID: 31413534
[TBL] [Abstract][Full Text] [Related]
8. Managing skin toxicities related to panitumumab.
Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
[TBL] [Abstract][Full Text] [Related]
9. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.
Lacouture ME; Mitchell EP; Piperdi B; Pillai MV; Shearer H; Iannotti N; Xu F; Yassine M
J Clin Oncol; 2010 Mar; 28(8):1351-7. PubMed ID: 20142600
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.
Hofheinz RD; Deplanque G; Komatsu Y; Kobayashi Y; Ocvirk J; Racca P; Guenther S; Zhang J; Lacouture ME; Jatoi A
Oncologist; 2016 Dec; 21(12):1483-1491. PubMed ID: 27449521
[TBL] [Abstract][Full Text] [Related]
12. EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Chiang TY; Hsu HC; Jane SW; Chen SC
Support Care Cancer; 2020 Oct; 28(10):4771-4779. PubMed ID: 31974771
[TBL] [Abstract][Full Text] [Related]
13. Skin problems and EGFR-tyrosine kinase inhibitor.
Kozuki T
Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous toxicities of epidermal growth factor receptor inhibitors: A prospective study in 60 Asian patients.
Chularojanamontri L; Tuchinda P; Likitwattananurak C; Pongparit K; Rujitharanawong C; Ithimakin S; Kulthanan K
Asian Pac J Allergy Immunol; 2019 Mar; 37(1):12-18. PubMed ID: 29549700
[TBL] [Abstract][Full Text] [Related]
15. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study.
Barbu MA; Niţipir C; Voiosu T; Giurcăneanu C
Rom J Intern Med; 2018 Jun; 56(2):96-101. PubMed ID: 29360630
[TBL] [Abstract][Full Text] [Related]
16. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
[TBL] [Abstract][Full Text] [Related]
17. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
[TBL] [Abstract][Full Text] [Related]
18. Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists.
Timmers L; Boons CC; Verbrugghe M; van den Bemt BJ; Van Hecke A; Hugtenburg JG
BMC Cancer; 2017 Feb; 17(1):122. PubMed ID: 28187759
[TBL] [Abstract][Full Text] [Related]
19. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.
Peuvrel L; Bachmeyer C; Reguiai Z; Bachet JB; André T; Bensadoun RJ; Bouché O; Ychou M; Dréno B
Support Care Cancer; 2012 May; 20(5):909-21. PubMed ID: 22361824
[TBL] [Abstract][Full Text] [Related]
20. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Bernier J; Bonner J; Vermorken JB; Bensadoun RJ; Dummer R; Giralt J; Kornek G; Hartley A; Mesia R; Robert C; Segaert S; Ang KK
Ann Oncol; 2008 Jan; 19(1):142-9. PubMed ID: 17785763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
